Clinical variability in Becker muscular dystrophy: Genetic, biochemical and immunohistochemical correlates

G. P. Comi, A. Prelle, N. Bresolin, M. Moggio, A. Bardoni, A. Gallanti, G. Vita, A. Toscano, M. T. Ferro, A. Bordoni, F. Fortunato, P. Ciscato, G. Felisari, S. Tedeschi, E. Castelli, R. Garghentino, A. Turconi, P. Fraschini, E. Marchi, G. G. NegrettoL. Adobbati, G. Meola, P. Tonin, A. Papadimitriou, G. Scarlato

Research output: Contribution to journalArticle

Abstract

We have investigated 59 Becker muscular dystrophy patients, representing 56 independent mutations, to test the hypothesis of predictability of muscle dystrophin expression and clinical phenotype based on location of dystrophin gene mutations. Partial intragenic deletions and duplications account for 82% of the independent mutations, of which 76.7% were deletions and 5.3% duplications. Mutations in which boundaries could be defined, were of in-frame type (35 out of 37, 94.6%), with two exceptions. Eighty-two percent of mutations were located at the distal part of the rod domain (exons 45-60), 9% at domain I (promoter through exon 9) and 9% at proximal and central parts of domain II. Domain I deleted patients tended to have a worse clinical phenotype, with earlier presentation, faster progression rate and lower dystrophin expression, while distal rod domain deleted patients showed a more classic Becker muscular dystrophy phenotype. Between these two groups only the differences in the immunohistochemical patterns of dystrophin expression and disease progression rate were statistically significant. Partial clinical and biochemical heterogeneity was observed in the distal domain II patient group, due to the presence of few patients covering the extremities of clinical severity. Two asymptomatic patients had deletions located in the central (exons 41-44) and distal parts (exons 50-53) of the rod domain. Severe myalgia and cramps were often reported as early onset symptoms (18 out of 59): no correlation was found between this symptomatology and the location of the mutation. Relative levels of muscle dystrophin correlated with immunohistochemical patterns of subsarcolemma staining. Dystrophin levels (as estimated by 30 kDa, antibody immuno-reactivity) correlated with age of reaching a moderate degree of muscle involvement as well as with delay in reaching that stage, a parameter of disease progression rate. Our data confirm that different Becker muscular dystrophy gene in-frame mutations have different effects on dystrophin expression and clinical severity, indicating several functional roles of the dystrophin domains.

Original languageEnglish
Pages (from-to)1-14
Number of pages14
JournalBrain
Volume117
Issue number1
Publication statusPublished - Feb 1994

Fingerprint

dystrophin
muscular dystrophy
Dystrophin
Duchenne Muscular Dystrophy
molecular genetics
Correlate
Muscle
Molecular Biology
Mutation
mutation
Genes
exons
Exons
Progression
Phenotype
Deletion
Antibodies
Duplication
phenotype
disease course

Keywords

  • Becker muscular dystrophy
  • Dystrophin
  • Dystrophin gene mutation

ASJC Scopus subject areas

  • Neuroscience(all)
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Mathematics(all)
  • Statistics and Probability
  • Agricultural and Biological Sciences (miscellaneous)
  • Clinical Neurology

Cite this

Clinical variability in Becker muscular dystrophy : Genetic, biochemical and immunohistochemical correlates. / Comi, G. P.; Prelle, A.; Bresolin, N.; Moggio, M.; Bardoni, A.; Gallanti, A.; Vita, G.; Toscano, A.; Ferro, M. T.; Bordoni, A.; Fortunato, F.; Ciscato, P.; Felisari, G.; Tedeschi, S.; Castelli, E.; Garghentino, R.; Turconi, A.; Fraschini, P.; Marchi, E.; Negretto, G. G.; Adobbati, L.; Meola, G.; Tonin, P.; Papadimitriou, A.; Scarlato, G.

In: Brain, Vol. 117, No. 1, 02.1994, p. 1-14.

Research output: Contribution to journalArticle

Comi, GP, Prelle, A, Bresolin, N, Moggio, M, Bardoni, A, Gallanti, A, Vita, G, Toscano, A, Ferro, MT, Bordoni, A, Fortunato, F, Ciscato, P, Felisari, G, Tedeschi, S, Castelli, E, Garghentino, R, Turconi, A, Fraschini, P, Marchi, E, Negretto, GG, Adobbati, L, Meola, G, Tonin, P, Papadimitriou, A & Scarlato, G 1994, 'Clinical variability in Becker muscular dystrophy: Genetic, biochemical and immunohistochemical correlates', Brain, vol. 117, no. 1, pp. 1-14.
Comi, G. P. ; Prelle, A. ; Bresolin, N. ; Moggio, M. ; Bardoni, A. ; Gallanti, A. ; Vita, G. ; Toscano, A. ; Ferro, M. T. ; Bordoni, A. ; Fortunato, F. ; Ciscato, P. ; Felisari, G. ; Tedeschi, S. ; Castelli, E. ; Garghentino, R. ; Turconi, A. ; Fraschini, P. ; Marchi, E. ; Negretto, G. G. ; Adobbati, L. ; Meola, G. ; Tonin, P. ; Papadimitriou, A. ; Scarlato, G. / Clinical variability in Becker muscular dystrophy : Genetic, biochemical and immunohistochemical correlates. In: Brain. 1994 ; Vol. 117, No. 1. pp. 1-14.
@article{67d1253a58f64e87aea3717f23c30ee2,
title = "Clinical variability in Becker muscular dystrophy: Genetic, biochemical and immunohistochemical correlates",
abstract = "We have investigated 59 Becker muscular dystrophy patients, representing 56 independent mutations, to test the hypothesis of predictability of muscle dystrophin expression and clinical phenotype based on location of dystrophin gene mutations. Partial intragenic deletions and duplications account for 82{\%} of the independent mutations, of which 76.7{\%} were deletions and 5.3{\%} duplications. Mutations in which boundaries could be defined, were of in-frame type (35 out of 37, 94.6{\%}), with two exceptions. Eighty-two percent of mutations were located at the distal part of the rod domain (exons 45-60), 9{\%} at domain I (promoter through exon 9) and 9{\%} at proximal and central parts of domain II. Domain I deleted patients tended to have a worse clinical phenotype, with earlier presentation, faster progression rate and lower dystrophin expression, while distal rod domain deleted patients showed a more classic Becker muscular dystrophy phenotype. Between these two groups only the differences in the immunohistochemical patterns of dystrophin expression and disease progression rate were statistically significant. Partial clinical and biochemical heterogeneity was observed in the distal domain II patient group, due to the presence of few patients covering the extremities of clinical severity. Two asymptomatic patients had deletions located in the central (exons 41-44) and distal parts (exons 50-53) of the rod domain. Severe myalgia and cramps were often reported as early onset symptoms (18 out of 59): no correlation was found between this symptomatology and the location of the mutation. Relative levels of muscle dystrophin correlated with immunohistochemical patterns of subsarcolemma staining. Dystrophin levels (as estimated by 30 kDa, antibody immuno-reactivity) correlated with age of reaching a moderate degree of muscle involvement as well as with delay in reaching that stage, a parameter of disease progression rate. Our data confirm that different Becker muscular dystrophy gene in-frame mutations have different effects on dystrophin expression and clinical severity, indicating several functional roles of the dystrophin domains.",
keywords = "Becker muscular dystrophy, Dystrophin, Dystrophin gene mutation",
author = "Comi, {G. P.} and A. Prelle and N. Bresolin and M. Moggio and A. Bardoni and A. Gallanti and G. Vita and A. Toscano and Ferro, {M. T.} and A. Bordoni and F. Fortunato and P. Ciscato and G. Felisari and S. Tedeschi and E. Castelli and R. Garghentino and A. Turconi and P. Fraschini and E. Marchi and Negretto, {G. G.} and L. Adobbati and G. Meola and P. Tonin and A. Papadimitriou and G. Scarlato",
year = "1994",
month = "2",
language = "English",
volume = "117",
pages = "1--14",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Clinical variability in Becker muscular dystrophy

T2 - Genetic, biochemical and immunohistochemical correlates

AU - Comi, G. P.

AU - Prelle, A.

AU - Bresolin, N.

AU - Moggio, M.

AU - Bardoni, A.

AU - Gallanti, A.

AU - Vita, G.

AU - Toscano, A.

AU - Ferro, M. T.

AU - Bordoni, A.

AU - Fortunato, F.

AU - Ciscato, P.

AU - Felisari, G.

AU - Tedeschi, S.

AU - Castelli, E.

AU - Garghentino, R.

AU - Turconi, A.

AU - Fraschini, P.

AU - Marchi, E.

AU - Negretto, G. G.

AU - Adobbati, L.

AU - Meola, G.

AU - Tonin, P.

AU - Papadimitriou, A.

AU - Scarlato, G.

PY - 1994/2

Y1 - 1994/2

N2 - We have investigated 59 Becker muscular dystrophy patients, representing 56 independent mutations, to test the hypothesis of predictability of muscle dystrophin expression and clinical phenotype based on location of dystrophin gene mutations. Partial intragenic deletions and duplications account for 82% of the independent mutations, of which 76.7% were deletions and 5.3% duplications. Mutations in which boundaries could be defined, were of in-frame type (35 out of 37, 94.6%), with two exceptions. Eighty-two percent of mutations were located at the distal part of the rod domain (exons 45-60), 9% at domain I (promoter through exon 9) and 9% at proximal and central parts of domain II. Domain I deleted patients tended to have a worse clinical phenotype, with earlier presentation, faster progression rate and lower dystrophin expression, while distal rod domain deleted patients showed a more classic Becker muscular dystrophy phenotype. Between these two groups only the differences in the immunohistochemical patterns of dystrophin expression and disease progression rate were statistically significant. Partial clinical and biochemical heterogeneity was observed in the distal domain II patient group, due to the presence of few patients covering the extremities of clinical severity. Two asymptomatic patients had deletions located in the central (exons 41-44) and distal parts (exons 50-53) of the rod domain. Severe myalgia and cramps were often reported as early onset symptoms (18 out of 59): no correlation was found between this symptomatology and the location of the mutation. Relative levels of muscle dystrophin correlated with immunohistochemical patterns of subsarcolemma staining. Dystrophin levels (as estimated by 30 kDa, antibody immuno-reactivity) correlated with age of reaching a moderate degree of muscle involvement as well as with delay in reaching that stage, a parameter of disease progression rate. Our data confirm that different Becker muscular dystrophy gene in-frame mutations have different effects on dystrophin expression and clinical severity, indicating several functional roles of the dystrophin domains.

AB - We have investigated 59 Becker muscular dystrophy patients, representing 56 independent mutations, to test the hypothesis of predictability of muscle dystrophin expression and clinical phenotype based on location of dystrophin gene mutations. Partial intragenic deletions and duplications account for 82% of the independent mutations, of which 76.7% were deletions and 5.3% duplications. Mutations in which boundaries could be defined, were of in-frame type (35 out of 37, 94.6%), with two exceptions. Eighty-two percent of mutations were located at the distal part of the rod domain (exons 45-60), 9% at domain I (promoter through exon 9) and 9% at proximal and central parts of domain II. Domain I deleted patients tended to have a worse clinical phenotype, with earlier presentation, faster progression rate and lower dystrophin expression, while distal rod domain deleted patients showed a more classic Becker muscular dystrophy phenotype. Between these two groups only the differences in the immunohistochemical patterns of dystrophin expression and disease progression rate were statistically significant. Partial clinical and biochemical heterogeneity was observed in the distal domain II patient group, due to the presence of few patients covering the extremities of clinical severity. Two asymptomatic patients had deletions located in the central (exons 41-44) and distal parts (exons 50-53) of the rod domain. Severe myalgia and cramps were often reported as early onset symptoms (18 out of 59): no correlation was found between this symptomatology and the location of the mutation. Relative levels of muscle dystrophin correlated with immunohistochemical patterns of subsarcolemma staining. Dystrophin levels (as estimated by 30 kDa, antibody immuno-reactivity) correlated with age of reaching a moderate degree of muscle involvement as well as with delay in reaching that stage, a parameter of disease progression rate. Our data confirm that different Becker muscular dystrophy gene in-frame mutations have different effects on dystrophin expression and clinical severity, indicating several functional roles of the dystrophin domains.

KW - Becker muscular dystrophy

KW - Dystrophin

KW - Dystrophin gene mutation

UR - http://www.scopus.com/inward/record.url?scp=0028347196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028347196&partnerID=8YFLogxK

M3 - Article

C2 - 8149204

AN - SCOPUS:0028347196

VL - 117

SP - 1

EP - 14

JO - Brain

JF - Brain

SN - 0006-8950

IS - 1

ER -